Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors (VEGFR), in combination with carboplatin (C) + paclitaxel (T) in patients with advanced non-small cell lung cancer (NSCLC): A study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)
Scott A. Laurie(Ottawa Hospital), Leonard W. Seymour(University of Oxford), Andrew Arnold(University of Connecticut), Peter Ellis(Oldham Council), Frances A. Shepherd(University Health Network), S. Matthews(University of Washington), L. Gauthier(Vanderbilt University), Glenwood Goss(Ottawa Hospital), Jane Robertson(Cancer Research UK), E. Chen(AstraZeneca (Canada))
Cited by 29
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
High burden and pervasive positive selection of somatic mutations in normal human skin
|Science|2015|1.8k
Clinical and biological implications of driver mutations in myelodysplastic syndromes
|Blood|2013|1.8k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k